From The Globe and Mail: Canadian governments should not pay for a $250,000-a-year cystic fibrosis medication because it is not clear the drug actually improves patients’ health, according to a fresh review that has devastated some with the potentially fatal lung disease.... In a report released on Thursday, the CADTH’s expert panel said its review … Continue reading Is the US setting the bar too low for new CF drug? Canada says it’s not worth it
Robert Weisman of the Globe reports today: California scientist Paul M. Quinton learned that he has cystic fibrosis at age 19 and has spent his long career in his lab working on ways to cure it. He is, in short, not the kind of person you’d expect to be fighting with Vertex Pharmaceuticals Inc., the … Continue reading Why won’t the Cystic Fibrosis Foundation comment on the high price of the new Vertex drug?
It sounds kind of hostile, but "clawback" is an economic development term. Instead of using flat-out tax breaks to lure companies that promise new jobs, the Massachusetts Life Science Initiative now holds firms to their promises. If they don't generate jobs, companies have to pay back the state. So, Vertex, the Cambridge biotech that just … Continue reading Vertex gets clawed after sales of much-touted hepatitis C drug drop
...with $11.8 million from Boston taxpayers. The Globe today reports that the biotech firm Vertex plans to build a $2 billion waterfront tower in Boston. Vertex yesterday signed a letter of intent to relocate its headquarters from Cambridge to the Fan Pier complex in late 2013. The 23-acre development has just one tower now, but … Continue reading The house that hepatitis built